Key Findings
Lonza has introduced its ‘Rapid Custom Media Prototyping Service (RaMP)’ designed to significantly accelerate early-stage bioprocess development. This new service enables biopharmaceutical companies to obtain custom liquid and powder media for screening, process verification, and early development within a groundbreaking timeframe of just 10 business days. This addresses long-standing challenges of extended lead times and limited small-batch production options in custom media procurement, supporting faster development cycles and a smoother transition to GMP manufacturing.
Technical & Clinical Details
In biopharmaceutical development, optimizing cell culture media is a critical factor determining product yield and quality. However, the development and procurement of custom media have historically been complex and time-consuming processes, often creating bottlenecks in early development stages. Lonza’s RaMP service is specifically designed to alleviate this challenge.
- Rapid Supply System: The RaMP service offers custom media batches of 1–10 kg for non-GMP powder and 1–100 L for liquid, delivered within 10 business days from order placement. This speed allows for rapid experimental cycles in discovery research and early process development, accelerating iterative development.
- Flexible Production Capacity: The ability to handle small-to-medium-sized custom media batches enables efficient testing of diverse media compositions required for early screening and optimization phases. This ensures that developers can confidently identify optimal media formulations before progressing to full-scale GMP manufacturing.
- Pathway to GMP Manufacturing: Optimized media formulations derived from the RaMP service can be seamlessly scaled up to GMP-compliant commercial production, leveraging Lonza’s comprehensive CDMO services. This continuity ensures consistent quality and efficiency throughout the entire development lifecycle.
- Quality and Expertise: Lonza’s extensive experience and expertise in media development form the foundation of the RaMP service. High-quality raw materials and stringent quality control processes ensure the reliability of custom media provided.
Background & Industry Context
The rapid growth of the biopharmaceutical market, particularly in novel modalities like cell and gene therapies, has intensified the need for faster and more efficient development and manufacturing processes. Rapid supply of custom media is essential for companies to gain a competitive edge in this highly dynamic market. The provision of such services by a leading CDMO like Lonza plays a crucial role in fostering industry-wide innovation and accelerating the market entry of new therapies.
Strategic Significance & Outlook
Lonza’s RaMP service addresses a critical bottleneck in biopharmaceutical development, significantly enhancing R&D agility. This will likely accelerate the progression of new biopharmaceutical candidates into clinical trials and ultimately to patients. Researchers and development engineers can explore more media designs and increase optimization opportunities, while investors can anticipate faster market entry driven by reduced development timelines and improved cost-efficiency. This service is expected to have a particularly significant impact on the development of personalized medicine and orphan drug therapies.
Source: https://manufacturingchemist.com/lonza-launches-rapid-custom-media-prototyping-service-to-1
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments